Holen Sie sich die Stockscreener-App
2.10
7.89%
-0.18
Vorhandelsmarkt:
2.07
-0.03
-1.43%
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Jasper Therapeutics Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
JSPR SEC FilingsJasper Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Jasper Therapeutics, Inc. (JSPR), Quanex Building Products Corporation (NX), and RCI Hospitality Holdings, Inc. (RICK) - GlobeNewswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria - MSN
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Sahm
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options - Lelezard
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain OfficersJSPR - Lelezard
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
Boston Herald - FinancialContent
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications - TipRanks
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
JSPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Lelezard
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Is Jasper Therapeutics Inc Equity Warrant a good long term investmentMarket Rumors and News & Minimal Investment Trading Tips - earlytimes.in
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Jasper Therapeutics ... - Bluefield Daily Telegraph
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Lelezard
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR - FinancialContent
JSPR Stockholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Jasper Therapeutics ... - Black Hills Pioneer
What analysts say about Jasper Therapeutics Inc Equity Warrant stockMarket Profile Overview & Budget Friendly Trading Alerts - earlytimes.in
Can Jasper Therapeutics Inc. stock weather global recessionMonthly Report 2025 & Develop Consistency in Trading Habits - nchmf.gov.vn
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Shareholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JSPR Investors Should Contact Robbins LLP Regarding the - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
What analysts say about Jasper Therapeutics Inc stockEconomic Indicators Overview & Explore Stocks for Free with Our Research Portal - earlytimes.in
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):